Phase 2 Study Comparing Curcumin Supplement Versus Placebo to Reduce Inflammation and Improve Symptoms in Patients with Clonal Cytopenia, Low-Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

What this Trial Is About

Researchers are evaluating the effects of a curcumin supplement C3 complexBioperine on inflammation and symptoms in patients with clonal cytopenia of undetermined significance CCUS, low-risk myelodysplastic syndrome LR-MDS, and myeloproliferative neoplasms MPN. Chronic inflammation plays a role in the development of these diseases and contributes to patient symptoms. Curcumin is being studied for its anti-inflammatory and anti-cancer properties in these blood disorders. Participants are randomly assigned to one of two groups one group receives the curcumin supplement orally twice daily for 12 months unless disease progression or unacceptable side effects occur, while the other group receives a placebo on the same schedule. Both groups undergo bone marrow aspiration and biopsy at the start and during follow-up, along with regular blood sample collection. During the study, participants undergo assessments of inflammatory cytokine levels and symptom scores at baseline, 3 months, and 12 months. Researchers also monitor changes in genetic mutations, DNA methylation patterns, and blood cell counts after 12 months. Safety is closely tracked through frequent visits during the first three months and every three months thereafter for a total of 12 months. After treatment, participants are followed annually for up to 10 years to monitor long-term effects and transfusion needs.

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms